The estimated Net Worth of Venture Associates X, L.P.A... is at least $41.3 Milión dollars as of 7 April 2021. Venture A owns over 127,095 units of Kymera Therapeutics stock worth over $6,298,333 and over the last 4 years Venture sold KYMR stock worth over $34,958,944.
Venture has made over 4 trades of the Kymera Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Venture sold 242,133 units of KYMR stock worth $14,770,113 on 11 August 2021.
The largest trade Venture's ever made was selling 242,133 units of Kymera Therapeutics stock on 11 August 2021 worth over $14,770,113. On average, Venture trades about 184,815 units every 38 days since 2021. As of 7 April 2021 Venture still owns at least 140,682 units of Kymera Therapeutics stock.
You can see the complete history of Venture A stock trades at the bottom of the page.
Over the last 4 years, insiders at Kymera Therapeutics have traded over $179,227,903 worth of Kymera Therapeutics stock and bought 2,497,406 units worth $70,844,455 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Bros. Advisors Lp667, L.P.B... a Group, Llc Green Jeremy Red.... On average, Kymera Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,989,455. The most recent stock trade was executed by Jeffrey W. Albers on 26 August 2024, trading 5,000 units of KYMR stock currently worth $51,700.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics executives and other stock owners filed with the SEC include: